Drug intelligence / Profile preview

EP-202

Development stage: Preclinical
Lead developer: EndoPure Life Sciences
Modality: Small Molecules

Overview

EP-202 is a small molecule cannabinoid composition developed by EndoPure Life Sciences, currently in the IND-enabling phase for the treatment of chronic inflammatory pain. The drug is designed to selectively target the peripheral endocannabinoid system, aiming to provide potent analgesic and anti-inflammatory effects. By focusing on peripheral targets, EP-202 is intended to avoid the central nervous system (CNS) mediated psychotropic side effects often associated with systemic cannabinoid therapies. This approach leverages the natural pain-modulating pathways of the endocannabinoid system while maintaining a favorable safety profile for long-term management of inflammatory conditions.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on EP-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-202.

Explore the full profile